Evidence map›Paper›PMID 27774826›Full record

ArticleRenal failure2017

Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy.

Amal H Hamza, Widad M Al-Bishri, Laila A Damiati, Hanaa H Ahmed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Stem cell-based treatment of kidney diseases.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Amal H Hamzaa Biochemictry Department, Faculty of Science Al Faisalia , King Abdulaziz University , Jeddah , Saudi Arabia.
Widad M Al-Bishria Biochemictry Department, Faculty of Science Al Faisalia , King Abdulaziz University , Jeddah , Saudi Arabia.
Laila A Damiatic Biology Department, Faculty of Science , University of Jeddah , Jeddah , Saudi Arabia.
Hanaa H Ahmedd Hormones Department , National Research Centre , Dokki , Giza , Egypt.
King Abdulaziz University · SAJeddah University · SANational Research Centre · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe progresses made in stem cell therapy offer an innovative approach and exhibit great potential for the repair of damaged organs and tissues. This study was conducted with a view to find the mechanisms responsible for the effectiveness of bone marrow-derived mesenchymal stem cells (BM-MSCs) in the suppression of diabetes and experimentally-induced diabetic nephropathy.

methodsTo realize this objective, diabetic and diabetic nephropathy subject groups that underwent MSC treatment were studied through numerous biochemistry and molecular genetics analyses.

resultsThe findings show that, relative to the control groups, the rats in the diabetic and diabetic nephropathy groups treated with stem cells infused with BM-MSCs showed a significant reversal in the levels of their insulin, glucose, heme-oxygenase-1 (HO-1) serum, and advanced glycation end product (AGEP). Moreover, BM-MSC therapy was also found to have a definite positive effect on the kidney functions. In addition, it also corresponded with a significant decrease in the availability of certain growth factors, namely the fibroblast growth factor (FGF), the platelet-derived growth factor (PDGF), and the transforming growth factor-β (TGF-β). BM-MSC treatment also improved the levels of expression of monocyte chemoatractant-1 (MCP-1) and interleukin-8 (IL-8) genes within kidney tissues. Lastly, the treatment recovered the organizational structure of the kidney and pancreas, a result demonstrated by a histopathological analysis. These results greatly coincide with those obtained through the biochemistry and molecular genetics analyses.

conclusionTreatment using BM-MSCs is determined to be definitely effective in cases of diabetes and diabetic nephropathy.

Indexed as

Diabetic NephropathiesAnimalsBiomarkersBlood GlucoseDiabetes Mellitus, ExperimentalDisease Models, AnimalGlycation End Products, AdvancedHeme Oxygenase-1InsulinKidneyMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPancreasRatsTreatment OutcomeBiomarkersBlood GlucoseGlycation End Products, AdvancedHeme Oxygenase-1InsulinDiabetesdiabetic nephropathygrowth factorsinflammatory mediatorsoxidative stress markersstem cells

Identifiers

PMID27774826
PMCPMC6014323
OpenAlexW2537664736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.